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Electrolytic copper as cheap and 
effective catalyst for one-pot 
triazole synthesis
Jacek Mularski, Barbara Czaplińska, Wioleta Cieślik, Jakub Bebłot, Piotr Bartczak, Rafał Sitko, 
Jarosław Polański & Robert Musiol
Electrolytic copper is a well-known form of pure, oxygen free copper that is used for industrial 
applications. In this work, the catalytic potential of this relatively cheap material was studied. The 
addition of less than 0.015 mol equivalent of copper powder effectively catalysed the one-pot synthesis 
of triazoles from a diverse range of organic halides and alkynes. Quantitative conversions in aqueous 
solvents can be achieved within minutes. The heterogenous nature of the catalyst afforded a low level 
of copper contamination in the products, thus meeting the rigorous criteria of the pharmaceutical 
industry.
The 1,3-dipolar cycloaddition between an azide and alkyne is a prime example of a click chemistry reaction. This 
approach allows 1,4 or 1,5-substituted 1,2,3-triazoles to be created in an elegant way1,2. These important molec-
ular scaffolds are not readily available through alternative methods3. Triazoles have become crucial in medicinal 
chemistry and drug synthesis where biologically oriented patterns do not comply with the products of typical 
carbonyl chemistry2.
The discovery of the catalytic properties of copper4 or ruthenium compounds in these reactions has extended 
their synthetic utility. Copper (II) sulfates and acetates combined with sodium ascorbate under aqueous condi-
tion are especially favorable for generating Cu(I) in situ in order to create intermediate acetylides required for the 
dipolar cycloaddition. Water appears to be an ideal solvent to stabilize copper(I) acetylides against aggregated, 
unreactive forms5. Such protocols have been widely adopted due to their effectiveness and versatility. At the same 
time, however, the use of toxic heavy metals in aqueous solutions cause environmental concerns. Dissolved met-
als affect the costs of the synthesis, particularly in medicinal chemistry and pharmaceutical applications where 
strict requirements regulate the level of heavy-metal impurities in pharmaceutical materials. Metal scavenging 
is another costly step, which also affects the R&D operational field. However, it is essential to eliminate biocidal 
copper from stocks that are designated for biological screening and therapeutic applications. Thus, alternatives 
to homogenous copper salt catalysts are Cu(I) species that are immobilized on solid supports such as silica, char-
coal or zeolites6. Recently, Cu nanoparticles have also been described in this regard. Kumar et al. reported the 
synthesis of triazoles from azides and alkynes in the presence of Cu nanoparticles that were suspended in guar 
gum7. Copper (II) oxide (CuO) has also proven to be effective as a nano-catalyst in Huisgen cycloadditions8. To 
date, various nanoparticles have been prepared and tested for click chemistry synthesis9–13. Copper nano-catalysts 
overcome several drawbacks of homogenous catalysis using Cu(I) soluble compounds. Notably, single-molecule 
spectroscopy supports a heterogeneous-catalysed mechanism of reaction14. Nevertheless, this approach still 
increases the costs of the synthesis. Moreover, some Cu nanoparticles are not free from stability problems13,15,16.
From a practical point of view, the discovery that metallic copper may, under specific conditions, provide an 
effective catalyst for dipolar cycloadditions, was a great advance. Cintas et al. described an approach that exploited 
ultrasound irradiation alone or in combination with microwave irradiation17 with copper turnings18. These 
approaches allowed saving time in comparison to conventional heating. Mechanical activation such as grinding 
with Cu powder under solvent-free conditions has also been be used19. On the other hand however latest report 
of Tumanov et al. suggest the tiny amount of water is crucial in such conditions20. These facts prompted us to 
investigate electrolytic copper as the easily available and cheap heterogenous catalyst candidate that combines all 
of the above described benefits. Our results confirm its superior performance in terms of efficiency and economy.
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Results
In our experiments, we selected a series of structurally diverse substrates including aromatic and aliphatic halides 
to test the overall activity of this catalyst. The experimental procedure consisted of mixing a benzyl bromide with 
sodium azide and a terminal acetylene group in water in the presence of electrolytic copper powder. The resulting 
mixture was heated at 85 °C until the substrates disappeared (TLC monitoring), then reaction was terminated and 
product isolated to provide yields that are presented in Table 1.
The most commonly used solvent in this dipolar cycloaddition is water. Mechanistically, the hydrogen bond-
ing potential between water molecules and substrates’ atoms is the reason for the unique reactivity of the organic 
compounds in this medium21 and may be responsible in some part for the initial removal of proton during the 
formation of intermediate acetylides. The reaction rate is enhanced even if insoluble substrates are stirred in an 
aqueous suspension22. In this case however, 10% addition of t-butyl alcohol improved the reaction. These reaction 
procedures appeared effective in synthesis of quinoline and quinazoline conjugates as is shown in Table 2.
Organic Azide Precursors. Good reactivity of the allyl iodide (Table 1) encouraged us to test other iodide 
as substrate. However iodides are used only accidentally for their higher costs in some cases, can be beneficial. 
For example 2-(iodomethyl)-4(3H)quinazolinone can be obtained easier with higher yield than corresponding 
bromide. To investigate reactivity substrates were reacted with TLC monitoring until full conversion, which was 
then confirmed based on 1H NMR of a crude product obtained by filtration. The results are presented in Table 3.
Catalyst Efficiency. Efficiency and reusability of the catalyst was tested subsequently on the exemplary reac-
tion. In short, 2 cm3 of water per equimolar 1 mmol of BnBr, and sodium azide was stirred in 85 °C with TLC 
monitoring to complete conversion, which was then confirmed by 1H NMR spectra of crude product. Work-up 
procedure was extraction with 3 × 50 cm3 of methylene chloride and concentration in vacuo. Additionally, we 
tested catalyst reusability. After the reaction product was transferred in hot ethyl acetate and the solvent was 
removed. Residuals was washed with DMF, then with water. We found thus clean copper catalyst which was then 
recycled. Results are presented in (Table 4).
substrates
Phenylacetylene a Hex-1-yne b Propargyl alcohol c
time[h]/yield[%] time [h]/yield [%] time [h]/yield [%]
BnBr 1 B; 2/97b,c B; 3/90b B; 2/96
p-Br·C6H4-CH2Br 2 B; 2/99 A; 1/99d A; 1/94
p-Cl·C6H4-CH2Br 3 B; 3/99 A; 1/72 A; 1/96
p-I·C6H4-CH2Br 4 B; 2/99b B; 2/99b A; 2/99b
2,3-Cl·C6H3-CH2Br 5 B; 2/93 B; 2/99 B; 2/99
n-BuBr 6 A; 24/94b,c — —
Allyl iodide 7 A; 1/99 — —
ethyl chloroacetate 8 A; 48/91b,d — —
4-bromobutyl acetate 9 A; 24/98 —
2-bromo-1-(4-methylphenyl)propan-1-one 10 A; 48/94e — A; 48/96e
1-fluoro-4-nitrobenzene 11 A; 24/8b — A; 24/10b
2-(bromomethyl)quinoline 12 B; 0.5/85c B; 0.5/85c B; 0.5/88c
Table 1. One-pot triazole synthesisa. aGeneral conditions: Copper powder, bromide, sodium azide and water. 
bOptionally 10% (v/v) of t-BuOH was added. cConditions B, alkyne was added into the reaction mixture by 
injection through a syringe after substrates’ premixing. dConditions A: Alkyne was added into the reaction 
mixture before vial capping. d24 h at RT then 24 h, 85 °C. eRT; Isolated yields.
Substrates
2-(bromomethyl)-
8-chloroquinoline
2-(bromomethyl)-
8-chloroquinoline
2-(bromomethyl) 
quinazolin-4(3H)-one
13 13b 14
time [h]/yield [%] time [h]/yield [%] time [h]/yield [%]
Phenylacetylene a B; 0.08/50 C; 24/71 B; 5/73c
Hex-1-yne b A; 24/65c C; 72/98 B; 1.5/73c
2-propyn-1-ol c B; 0.25/65 C; 24/69 B; 1/70c
3-butyn-2-ol d B; 0.35/50 C; 24/75 B; 0.5/72c
Benzyl propargyl ether e B; 0.5/60 C; 72/81 B; 0.25/95c
4-Ethynyl-N,N-dimethylaniline f B; 0.65/52 C; 72/72 B; 0.25/88c
Table 2. Quinoline and quinazoline triazole analogsa. aReaction conditions: see footnotes of Table 1. bClassical 
CuAAC method: (0.5 mmol of organic azide and 1 mmol of alkyne) 6 cm3 of t-BuOH, 10 mg L-ASC Na, 
Cu2(OAc)4(H2O)2 10 mg, Chromatografic sep. c10% of t-BuOH was added. Isolated yields.
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Homogenous Cu(I) catalysis may lead to a product that is considerably contaminated with residual copper23. 
Heterogenous catalysts are known to afford cleaner products. This prompted us to evaluate the residual cop-
per after a typical isolation and purification procedure. We used energy-dispersive X-ray fluorescence (EDXRF) 
spectroscopy to measure the copper level in the crude product (filtered from the reaction media) and after one of 
purification steps, as presented in Table 5.
Discussion
In general electrolytic copper appeared very effective in catalyzing triazole formation in one-pot cascade synthe-
sis. As presented in Table 1 most of the isolated yields reached quantitative level. Interestingly compounds 11a 
and 11c were obtained in low yield. On the other hand these have been reported only as trace of product in former 
work of Kafle and Handy24.
The Cu(II) reduction step, which is essential during conventional procedure, has to be performed before the 
addition of alkyne5. This require specific regime of the procedure with subsequential mixing of the reagents. In 
heterogenic Cu catalyst this should be irrelevant. To verify this hypothesis, we performed several experiments by 
mixing all of the chemicals immediately and then engaging the heat (condition A). Others were performed by 
introducing the alkyne in the final step after the temperature of the reaction mixture had reached 85 °C (condition 
B). No significant differences were observed between the outcomes of these two procedures. No apparent change 
was noted during one hour of agitation at 85 °C when the terminal alkyne was introduced into the aqueous sus-
pension of electrolytic copper. The copper particles form a sediment and the alkyne phase floated. After a solution 
of sodium azide and organic bromide was introduced to this mixture, the triazole product was formed quantita-
tively. This experiment indicates that the alkyne substrate may be introduced before or following the addition of 
bromide and sodium azide.
The same reaction procedure when needed was modified by addition of co-solvent was successfully applied 
to synthesis of quinolines and quinazolines where it shows advantage over conventional approach. As presented 
in Table 2 syntheses can be successfully completed in short time. The exceptions were compounds 13b and 14a, 
Substratesb
2-(bromomethyl) 
quinazolin-4(3H)-one
2-(iodomethyl) 
quinazolin-4(3H)-one
14 15
Time [h]
Phenylacetylene a 5 24
Hex-1-yne b 1.5 24
2-propyn-1-ol c 1 24
3-butyn-2-ol d 0.5 24
Table 3. Comparison of iodides and bromides as substrates in one-pot triazole synthesisa. aAll of the 
conversions >99%, b10% (v/v) t-BuOH was added.
Cu [eq. mol] Conversion [%] Time [h]
0.01 99 2
0.01a 99 2
0.01a 99 2
0.01a 99 2
4 × 10–4 99 2
2 × 10–4 56 24
1 × 10–4 22 24
Table 4. Catalyst efficiency. acatalyst reused.
Purification method Cu [ppm]
Filtrated crude product 967
Centrifuged (5000 RPM) 270
Filtrated (20 nm pores) 67
Recrystallized from EtOAc 11
Table 5. Experiment for the removal of copper particulates from crude triazolea. aTriazole (1a) was synthesized 
following conditions B: BnBr, Phenylacetylene, 0.015 eq of copper catalyst, 2 h, 85 °C.
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that required a considerably longer heating time. Quinazoline derivatives have a tendency to aggregate in aqueous 
solution, thus all reactions with this substrate require the presence of a t-BuOH.
The reports on one-pot triazole synthesis using organic halides as the starting material have mainly focused 
on bromides. We decided to test if iodides can be used in this reaction. Iodides as precursors have limited value 
for industrial application, due to high costs. From the point of view small scale laboratory synthesis, however it 
is interesting to test such possibility. Particularly in our experience with heteroaromatic moieties as quinoline 
and quinazoline where iodides can be obtained easier with higher yields. For example 2-(iodomethyl)quinolines 
are attractive alternative to the corresponding bromides25,26. On the other hand, concerns about the formation 
of 5-iodotriazoles have been outlined27–29. Moreover chemical system that contains copper, iodine and alkyne 
species is known susceptible to conglomeration30. One example of a one-pot triazole synthesis that engages an 
organic iodide (2 eq. of benzyl iodide, 1 eq. of terminal alkyne) describes the use of DMSO as the solvent, 0.16 
eq of Et3N as the adjuvant, 0.16 eq of copper (I) iodide as the catalyst and 0.16 eq of proline as a copper ligand31. 
Two quinazolinone halides 14 and 15 were selected for this experiment. Reactions were conducted until complete 
conversions and time is presented in Table 3. Those results suggest that iodides can be as effective as bromides 
ensuring high conversions and yields even if required considerably longer reaction times.
Metal-catalyzed chemical processes used on a technical or industrial scale are commonly based on heteroge-
neous catalysts as these facilitate the work-up operations and provide virtually metal-free products. Such catalysts 
can be expensive and are usually adapted to custom layouts. Thus their reusability is of high economic priority. In 
the case of electrolytic copper the advantage lies in its price. To say, recycling of cheap and readily available cata-
lyst may be economically unreasonable. Nevertheless it is important for describing its applicability and may cast a 
light on mechanistic features. For example digestion of the catalytic surface may lead to loss of activity. Moreover 
possibility to reuse the catalyst is highly recommended for green chemistry principles. During our experiments 
electrolytic copper appeared to retain its activity in subsequent conversions.
Another appealing property of heterogenic catalysis is a tendency to provide cleaner products, not contam-
inated by heavy metals. This is of special importance in drug synthesis where pharmacopeal regulations very 
strictly limits level of copper32. Although the crude product, filtered from our reaction mixture had a significant 
amount of Cu (0.1%), it can be considerably diminished using simple purification steps. A single crystallization 
from ethyl acetate afforded a pure product. Residual amount of copper in obtained product is lower than FDA 
guideline limits that suggest 250 ppm for oral administration and 25 ppm for parenteral use32.
Electrolytic copper powder is an effective catalyst for cascade triazole synthesis. There are several advantages 
in using this electrolytic copper catalyst. Its price and wide availability makes it interesting alternative to specific 
nanoparticulated versions. Powder of copper catalyst could be also isolated and reused maintaining its high activ-
ity. There is no need to use a reducing agent to maintain catalytic activity. In addition, the mixing order does not 
affect the reaction as it does in conventional homogenous click chemistry. Organic iodides may be used as well as 
bromides according to availability and needs. Simple isolation and purification resulted in pure products that had 
small amount of residual copper and thus are suitable for biological testing. What is noticeable use of electrolytic 
copper considerably reduce amounts of wastes, particularly water insoluble, organic phase. Another appealing 
aspects of these new method are equimolar amounts of substrates and overall simplicity of the procedure with 
less steps and chemicals in use.
Methods
Materials. The Fourier transform nuclear magnetic resonance spectra of the sample solutions were obtained 
using a Bruker Avance 400 spectrometer for 1H (400 MHz), 13C{1H} (101 MHz) and a Bruker Ascend 500 for 
1H (500 MHz), 13C{1H} (126 MHz). Chemical shifts were reported in δ units (parts per million) relative to 
tetramethylsilane and the residual solvent peaks were used as a reference. High-resolution mass spectra were 
measured using a DionexUltiMate® 3000 high-performance liquid chromatograph (Thermo Fisher Scientific, 
West Palm Beach, FL, USA) coupled with an LTQ Orbitrap XL™ Hybrid Ion Trap-Orbitrap Fourier Transform 
Mass Spectrometer (Thermo Fisher Scientific) with an injection into HESI II in the positive or negative modes. 
Chromatographic separations were done on a Teledyne ISCO Combiflash Rf150+ . The melting point was deter-
mined on an MPA100 Melting Point Apparatus from Stanford Research Systems. The chemical analysis was per-
formed using an Epsilon 3 energy-dispersive X-ray fluorescence (EDXRF) spectrometer (Panalytical, Almelo, 
The Netherlands) with a Rh target X-ray tube operating at the max. voltage of 30 keV and max. power of 9 W. The 
spectrometer was equipped with a thermoelectrically cooled silicon drift detector (SDD) with an 8 μm Be window 
and a resolution of 135 eV at 5.9 keV. The quantitative analysis was performed using Omnian software and based 
on the fundamental parameter method for matrix correction. The copper was determined using K-alphaline 
and the following measurement conditions: 30 kV, 120 s counting time, air atmosphere and a 100 μm Ag primary 
beam filter. The current of the X-ray tube was fixed to not exceed a dead-time loss of ca. 50%.
The materials, which were purchased from commercial sources, were used without further purifica-
tion: 1-hexyne, propargyl alcohol, benzyl bromide, 2-Bromo-1-(4-methylphenyl)-1-propanone, 1-Fluoro-
2-nitrobenzene, allyl iodide, ethyl chloroacetate, 4-bromobutyl acetate, 1-bromobutane, sodium azide, 
tert-butyl alcohol, 230 mesh copper (Sigma-Aldrich); 2-methylquinoline, the pre-coated silica gel 60 F254 TLC 
plates, syringe filters with 20 nm pores (Merck); silica-gel 40–60 µm, 60 Å, phenylacetylene, 4-bromobenzyl 
bromide, 4-chlorobenzyl bromide, 4-iodobenzyl bromide, 1-(bromomethyl)-2,3-dichlorobenzene, 
8-chloro-2-methylquinoline, ethyl acetate Ph. Eur, dichloromethane Ph. Eur., hexane Ph. Eur. (Acros Organics); 
2-methyl-4(3H)-quinazolinone (Infinite Fine Chemicals). Water was purified by simple distillation.
Syntheses. Reactions were carried out in 12 cm3 septum-sealed vials. If not otherwise specified, the reactions 
were prepared by mixing the reagents in the following order: copper powder (1 mol%), organic azide precur-
sor (1 mmol of benzyl bromides, 0.50 mmol of quinoline and quinazolinone analogues), sodium azide (1 eq. 
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respectively to a precursor) and 2 cm3 of water. Optionally, 10% (v/v) of tert-butyl alcohol was added. Finally, 
terminal alkyne (1 eq. respectively to a precursor) was introduced either at RT and then the reaction mixture was 
heated to 85 °C, which resembled the batch approach (conditions A) or dropwise through a septum at the point at 
which the mixture reached 85 °C (conditions B). The progression of the reactions was monitored using TLC. Then 
50 cm3 of CH2Cl2, was added to a reaction mixture and the organic phase was washed with 50 cm3 of water, dried 
over anhydrous MgSO4 and evaporated under reduced pressure to yield a triazole. Alternatively, the crude solid 
was filtered and washed on a funnel with water and then with 5 cm3 of diethyl ether. NMR samples were prepared 
from the crude residue to measure the conversion. Recrystallization was employed to turn some viscous triazoles 
into a solid form if necessary. The yields of isolated triazoles are given.
1-benzyl-4-phenyl-1H-1,2,3-triazole (1a). Synthesized according to conditions B of the general procedure. 
Benzyl bromide (1 mmol, 171 mg), phenylacetylene (1 mmol, 102 mg), sodium azide (1 mmol, 65 mg). After 2 h 
the first work-up protocol was executed. 229 mg (97%) of green solid was obtained; mp: 123–125 °C (lit.33 126–
127 °C); 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.65 (s,1H, CH), 7.85–7.92 (m, 2H, Ar), 7.28–7.48 (m, 8H, Ar), 
5.67 (s, 2H, ArCH2N); 13C NMR (101 MHz; DMSO-d6; TMS): δ 147.2, 136.5, 131.17, 129.3, 129.2, 128.6, 128.4, 
125.7, 122.0, 53.5.
1-[(4-bromophenyl)methyl]-4-phenyl-1H-1,2,3-triazole (2a). Synthesized according to conditions B of the 
general procedure. 4-Bromobenzyl bromide (1 mmol, 250 mg), phenylacetylene (1 mmol, 102 mg), sodium 
azide (1 mmol, 65 mg). After 2 h the first work-up protocol was executed. 312 mg (99%) of light green solid was 
obtained; mp: 154–156 °C, (lit.34 156–158 °C); 1H NMR(400 MHz; DMSO-d6; TMS): δ 8.64 (1H, s, CH), 7.87 (d, 
J = 7.7 Hz, 2H, Ar), 7.59 (d, J = 8.1 Hz, 2H, Ar), 7.44 (d, J = 7.6 Hz, 2H, Ar), 7.33 (d, J = 8.0Hz, 1H, Ar), 5.66 (s, 2H, 
ArCH2N); 13C NMR (101 MHz; DMSO-d6; TMS): δ 147.2, 135.8, 132.2, 131.1, 130.6, 129.3, 128.4, 125.6, 122.1, 
121.9, 52.8.
1-[(4-chlorophenyl)methyl]-4-phenyl-1H-1,2,3-triazole (3a). Synthesized according to conditions B of the gen-
eral procedure. 4-Chlorobenzyl bromide (1 mmol, 206 mg), phenylacetylene (1 mmol, 102 mg), sodium azide 
(1 mmol, 65 mg); After 3 h the first work-up protocol was executed. 268 mg (99%) of light yellow-green solid was 
obtained; mp: 143–144 °C (lit.35 142–145 °C); 1H NMR(400 MHz; DMSO-d6; TMS): δ 8.65 (s, 1H, CH), 7.88 (d, 
J = 7.7 Hz, 2H, Ar), 7.28–7.48 (m, 7H, Ar), 5.68 (s, 2H, ArCH2N); 13C NMR (101 MHz; DMSO-d6; TMS): δ 147.2, 
135.4, 133.4, 131.1, 130.3, 129.4, 129.3, 128.4, 125.7, 122.1, 52.8.
1-[(4-iodophenyl)methyl]-4-phenyl-1H-1,2,3-triazole (4a). Synthesized according to conditions B of the general 
procedure. 4-Iodobenzyl bromide (1 mmol, 297 mg), phenylacetylene (1 mmol, 102 mg), sodium azide (1 mmol, 
65 mg), t-BuOH (0.2 cm3, 10% v/v). After 2 h the first work-up protocol was executed. 366 mg (99%) of yellow 
solid was obtained; mp: 139–141 °C (lit.36 154–156 °C); 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.63 (s, 1H, CH), 
7.87 (d, J = 7.6 Hz, 2H, Ar), 7.76 (d, J = 7.9 Hz, 2H, Ar), 7.44 (d, J = 7.7 Hz, 2H, Ar), 7.32 (t, J = 7.5 Hz, 1H, Ar), 
7.17 (d, J = 7.9 Hz, 2H, Ar), 5.63 (s, 2H, ArCH2N); 13C NMR (101 MHz; DMSO-d6; TMS): δ 147.2, 138.0, 136.2, 
131.1, 130.7, 129.3, 128.4, 125.7, 122.0, 94.9, 53.0.
1-[(2,3-dichlorophenyl)methyl]-4-phenyl-1H-1,2,3-triazole (5a, C15H11Cl2N3). Synthesized according to con-
ditions B of the general procedure. 1-(Bromomethyl)-2,3-dichlorobenzene (1 mmol, 240 mg), phenylacetylene 
(1 mmol, 102 mg), sodium azide (1 mmol, 65 mg). After 2 h the first work-up protocol was executed. 282 mg (93%) 
of beige solid was obtained; mp: 119–120 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.64 (s, 1H, CH), 7.88 
(d, J = 7.9 Hz, 2H, Ar), 7.66 (dd, J = 8.1 Hz, 1.2 Hz, 1H, Ar), 7.37–7.48 (m, 3H, Ar), 7.33 (appt, J = 7.4 Hz, 1H, 
Ar), 7.24 (d, J = 7.7 Hz, 1H, Ar), 5.82 (s, 2H, ArCH2N); 13C NMR (101 MHz; DMSO-d6; TMS): δ 147.0, 136.2, 
132.7, 131.3, 131.0, 129.5, 129.3, 129.1, 128.4, 125.7, 122.5, 51.8; HRMS (m/z): [M + H]+ calcd. for C15H1135Cl2N3, 
304.0403; found, 304.0409.
1-benzyl-4-butyl-1H-1,2,3-triazole (1b). Synthesized according to conditions B of the general procedure. Benzyl 
bromide (1 mmol, 171 mg), 1-hexyne (1 mmol, 82 mg), sodium azide (1 mmol, 65 mg), t-BuOH (0.2 cm3, 10% 
v/v). After 3 h the first work-up protocol was executed. 193 mg (90%) of green resin was obtained (lit.37 61–62 °C); 
1H NMR (400 MHz; DMSO-d6; TMS): δ 7.89 (s, 1H, CH), 7.24–7.41 (m, 5H, Ar), 5.53 (s, 2H, ArCH2N), 2.60 
(t, J = 7.6 Hz, 2H, CH2CH2CH2CH3), 1.56 (tt, J = 7.6 Hz, 2H, CH2CH2CH2CH3), 1.31 (tq, J = 7.3 Hz, 2H, 
CH2CH2CH2CH3), 0.89 (t, J = 7.3 Hz, 3H, CH2CH2CH2CH3). 13C NMR (101 MHz; DMSO-d6; TMS): δ 147.7, 
136.7, 129.2, 128.4, 128.2, 122.3, 53.1, 31.6, 25.1, 22.1, 14.1.
1-[(4-bromophenyl)methyl]-4-butyl-1H-1,2,3-triazole (2b). Synthesized according to conditions A of the gen-
eral procedure. 4-Bromobenzyl bromide (1 mmol, 250 mg), 1-hexyne (1 mmol, 82 mg), sodium azide (1 mmol, 
65 mg). After 1 h the first work-up protocol was executed. 291 mg (99%) of green solid was obtained; mp: 64–66 °C 
(lit.38 64–65 °C); 1H NMR (400 MHz; DMSO-d6; TMS): δ 7.90 (s, 1H, CH), 7.55 (d, J = 8.1 Hz, 2H, Ar), 7.25 (d, 
J = 8.1 Hz, 2H, Ar), 5.54 (s, 2H, ArCH2N), 2.60 (t, J = 7.6 Hz, 2H, CH2CH2CH2CH3), 1.55 (tt, J = 7.5 Hz, 2H, 
CH2CH2CH2CH3), 1.30 (tq, J = 7.4 Hz, 2H, CH2CH2CH2CH3), 0.87 (t, J = 7.4 Hz, 3H, CH2CH2CH2CH3); 13C 
NMR (101 MHz; DMSO-d6; TMS): δ 147.8, 136.1, 132.1, 130.5, 122.4, 121.8, 52.4, 31.5, 25.2, 22.2, 14.1.
4-butyl-1-[(4-chlorophenyl)methyl]-1H-1,2,3-triazole (3b). Synthesized according to conditions A of the gen-
eral procedure. 4-Chlorobenzyl bromide (1 mmol, 206 mg), 1-hexyne (1 mmol, 82 mg), sodium azide (1 mmol, 
65 mg). After 1 h the first work-up protocol was executed. 191 mg (72%) of light green solid was obtained; mp: 
58–60 °C (lit.39 52–54 °C); 1H NMR (400 MHz; DMSO-d6; TMS): δ 7.89 (s, 1H, CH), 7.41–7.46 (2H, m, Ar), 
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7.28–7.33 (m, 2H, Ar), 5.54 (s, 2H, ArCH2N), 2.60 (t, J = 7.6 Hz, 2H, CH2CH2CH2CH3), 1.55 (tt, J = 7.5 Hz, 2H, 
CH2CH2CH2CH3), 1.31 (tq, J = 7.4 Hz, 2H, CH2CH2CH2CH3), 0.88 (t, J = 7.4 Hz, 3H, CH2CH2CH2CH3); 13C 
NMR (101 MHz; DMSO-d6; TMS): δ 147.8, 135.7, 133.2, 130.2, 129.1, 122.4, 52.3, 31.5, 25.2, 22.2, 14.1.
4-butyl-1-[(4-iodophenyl)methyl]-1H-1,2,3-triazole (4b, C13H16IN3). Synthesized according to conditions 
B of the general procedure. 4-Iodobenzyl bromide (1 mmol, 297 mg), 1-hexyne (1 mmol, 82 mg), sodium 
azide (1 mmol, 65 mg), t-BuOH (0.2 cm3, 10% v/v);. After 2 h the first work-up protocol was executed. 341 mg 
(99%) of beige solid was obtained; mp: 94–95 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 7.88 (1H, s, CH), 
7.71–7.77 (m, 2H, Ar), 7.06–7.11 (m, 2H, Ar), 5.50 (s, 2H, ArCH2N), 2.60 (t, J = 7.6 Hz, 2H, CH2CH2CH2CH3), 
1.55 (tt, J = 7.6 Hz, 2H, CH2CH2CH2CH3), 1.31 (tq, J = 7.4 Hz, 2H, CH2CH2CH2CH3), 0.88 (t, J = 7.4 Hz, 3H, 
CH2CH2CH2CH3); 13C NMR (101 MHz; DMSO-d6; TMS): δ 147.8, 138.0, 136.5, 130.6, 122.4, 94.7, 52.6, 31.6, 
25.2, 22.2, 14.1; HRMS (m/z): [M + H]+ calcd. for C13H16IN3, 342.0462; found, 342.0464.
4-butyl-1-[(2,3-dichlorophenyl)methyl]-1H-1,2,3-triazole (5b, C13H15Cl2N3). Synthesized according to conditions 
B of the general procedure. 1-(Bromomethyl)-2,3-dichlorobenzene (1 mmol, 240 mg), 1-hexyne (1 mmol, 82 mg), 
sodium azide (1 mmol, 65 mg). After 2 h the first work-up protocol was executed. 281 mg (99%) of white crys-
tals was obtained; mp: 79–80 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 7.91 (s, 1H, CH), 7.64 (dd, J = 8.1 Hz, 
1.2 Hz, 1H, Ar), 7.38 (appt, J = 7.9 Hz, 1H, Ar), 7.09 (dd, J = 7.7 Hz, 1.1 Hz, 1H, Ar), 5.70 (s, 2H, ArCH2N), 2.62 (t, 
J = 7.6 Hz, 2H, CH2CH2CH2CH3), 1.57 (appquint, J = 7.5 Hz, 2H, CH2CH2CH2CH3), 1.31 (appsextet, J = 7.4 Hz, 
2H, CH2CH2CH2CH3), 0.88 (t, J = 7.4 Hz, 3H, CH2CH2CH2CH3); 13C NMR (101 MHz; DMSO-d6; TMS): δ 
147.6, 136.7, 132.6, 131.0, 130.8, 129.1, 129.0, 122.9, 51.4, 31.5, 25.1, 22.1, 14.1; HRMS (m/z): [M + H]+ calcd. for 
C13H1535Cl2N3, 284.0716; found, 284.0718.
(1-benzyl-1H-1,2,3-triazol-4-yl)methanol (1c). Synthesized according to conditions A of the general procedure. 
Benzyl bromide (1 mmol, 171 mg), propargyl alcohol (1 mmol, 56 mg), sodium azide (1 mmol, 65 mg); After 2 h 
the first work-up protocol was executed. 182 mg (96%) of beige solid was obtained; mp: 77–79 °C (lit.40 77–78 °C); 
1H NMR (400 MHz; DMSO-d6; TMS): δ 8.01 (s, 1H, CH), 7.28–7.40 (m, 5H, Ar), 5.57 (s, 2H, ArCH2N), 5.16 
(t, J = 5.7 Hz, 1H, OH), 4.51 (d, J = 5.5 Hz, 2H, CH2OH); 13C NMR (101 MHz; DMSO-d6; TMS): δ 148.8, 136.6, 
129.2, 128.6, 128.4, 123.3, 55.6, 53.2.
{1-[(4-bromophenyl)methyl]-1H-1,2,3-triazol-4-yl}methanol (2c). Synthesized according to conditions A of the 
general procedure. 4-Bromobenzyl bromide (1 mmol, 250 mg), propargyl alcohol (1 mmol, 56 mg), sodium azide 
(1 mmol, 65 mg); After 1 h the first work-up protocol was executed. 252 mg (94%) of pale beige solid was obtained; 
mp: 110–111 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.02 (s, 1H, CH), 7.58 (d, J = 8.0 Hz, 2H, Ar), 7.27 (d, 
J = 8.0 Hz, 2H, Ar), 5.56 (s, 2H, ArCH2N), 5.16 (t, J = 5.6 Hz, 1H, OH), 4.50 (d, J = 5.6 Hz, 2H, CH2OH); 13C NMR 
(101 MHz; DMSO-d6; TMS): δ 148.9, 136.0; 132.1; 130.6; 121.9, 123.4, 55.6, 52.5.
{1-[(4-chlorophenyl)methyl]-1H-1,2,3-triazol-4-yl}methanol (3c, C10H10ClN3O). Synthesized according to 
conditions A of the general procedure. 4-Chlorobenzyl bromide (1 mmol, 206 mg), propargyl alcohol (1 mmol, 
56 mg), sodium azide (1 mmol, 65 mg). After 1 h the first work-up protocol was executed. 215 mg (96%) of pale 
yellow solid was obtained; mp: 91–93 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.05 (s, 1H, CH), 7.40–7.47 
(m, 2H, Ar), 7.32–7.38 (m, 2H, Ar), 5.60 (s, 2H, ArCH2N), 5.22 (t, J = 5.7 Hz, 1H, OH), 4.55 (d, J = 5.7 Hz, 2H, 
CH2OH); 13C NMR (101 MHz; DMSO-d6; TMS): δ 148.9, 135.6, 133.3, 130.3, 129.2, 123.4, 55.5, 52.4; HRMS 
(m/z): [M + H]+ calcd. for C10H1035ClN3O, 224.0585; found, 224.0589.
{1-[(4-iodophenyl)methyl]-1H-1,2,3-triazol-4-yl}methanol (4c, C10H10IN3O). Synthesized according to condi-
tions A of the general procedure. 4-Iodobenzyl bromide (1 mmol, 297 mg), propargyl alcohol (1 mmol, 56 mg), 
sodium azide (1 mmol, 65 mg), t-BuOH (0.2 cm3, 10% v/v). After 2 h the first work-up protocol was executed. 
314 mg (99%) of white solid was obtained; mp: 139–140 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.02 (s, 1H, 
CH), 7.74 (d, J = 8.0 Hz, 2H, Ar), 7.12 (d, J = 8.0 Hz, 2H, Ar), 5.55 (s, 2H, ArCH2N), 5.19 (t, J = 5.3 Hz, 1H, OH), 
4.53 (d, J = 5.7 Hz, 2H, CH2OH); 13C NMR (101 MHz; DMSO-d6; TMS): δ 148.9, 138.0, 136.4, 130.7, 123.4, 94.8, 
55.5, 52.6; HRMS (m/z): [M + H]+ calcd. for C10H10IN3O, 315.9941; found, 315.9944.
{1-[(2,3-dichlorophenyl)methyl]-1H-1,2,3-triazol-4-yl}methanol (5c, C10H9Cl2N3). Synthesized according to con-
ditions B of the general procedure. 1-(Bromomethyl)-2,3-dichlorobenzene (1 mmol, 240 mg), propargyl alcohol 
(1 mmol, 56 mg), sodium azide (1 mmol, 65 mg). After 2 h the first work-up protocol was executed. 256 mg (99%) 
of off-white solid was obtained; mp: 111–112 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.03 (s, 1H, CH), 7.65 
(dd, J = 8.1 Hz, 1.2 Hz, 1H, Ar), 7.39 (appt, J = 7.9 Hz, 1H, Ar), 7.14 (dd, J = 7.7 Hz, 1.2 Hz, 1H, Ar), 5.75 (s, 2H, 
ArCH2N), 5.21 (t, J = 5.6 Hz, 1H, OH), 4.54 (d, J = 5.7 Hz, 2H, CH2OH); 13C NMR (101 MHz; DMSO-d6; TMS): 
δ 148.8, 136.6, 132.7, 131.1, 130.9, 129.3, 129.0, 123.8, 55.5, 51.5; HRMS (m/z): [M + H]+ calcd. for C10H935Cl2N3, 
258.0195; found, 258.0200.
1-butyl-4-phenyl-1H-1,2,3-triazole (6a). n-Bromobutane (1 mmol, 137 mg), phenylacetylene (1 mmol, 102 mg), 
sodium azide (1 mmol, 65 mg) was stirred for 24 h and the first work-up protocol was executed. 190 mg (94%) 
of off-white solid was obtained; mp: 46.0–47.5 °C (lit.41 46–47 °C); 1H NMR (500 MHz, CDCl3, TMS): δ 7.83 (d, 
J = 7.2 Hz, 2H, Ar), 7.74 (s, 1H, CH), 7.41 (t, J = 7.6 Hz, 2H, Ar), 7.32 (t, J = 7.5 Hz, 1H, Ar), 4.39 (t, J = 7.2 Hz, 
2H, NCH2CH2CH2CH3), 1.96–1.88(m, 2H, CH2CH2CH2CH3), 1.43–1.34 (m, 2H, CH2CH2CH2CH3), 0.97 (t, 
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J = 7.4 Hz, 3H, CH2CH2CH2CH3); 13C NMR (126 MHz, CDCl3, TMS): δ 147.6, 130.8, 128.8, 128.0, 125.6, 119.7, 
50.0, 32.2, 19.7, 13.4.
4-phenyl-1-(prop-2-en-1-yl)-1H-1,2,3-triazole (7a). 3-Iodopropene (1 mmol, 168 mg), phenylacetylene (1 mmol, 
102 mg), sodium azide (1 mmol, 65 mg) was stirred for 1 h and the first work-up protocol was executed. 185 mg 
(99%) of brownish-yellow solid was obtained; mp: 54.0–56.0 °C (lit.41 56–57 °C); 1H NMR (500 MHz, CDCl3, 
TMS): δ 7.84–7.81 (m, 2H, Ar), 7.76 (s, 1H, CH), 7.44–7.40 (m, 2H, Ar), 7.35–7.31 (m, 1H, Ar), 6.10–6.02 (m, 2H, 
CH2CH = CH2), 5.40–5.32 (m, 1H, CH2CH = CH2), 5.02 (appdt, J = 6.2 Hz, 1.4 Hz, 2H, CH2CH = CH2); 13C NMR 
(126 MHz, CDCl3, TMS): δ 147.8, 131.3, 130.6, 128.8, 128.1, 125.6, 120.0, 119.8, 52.6.
ethyl (4-phenyl-1H-1,2,3-triazol-1-yl)acetate (8a). Ethyl chloroacetate (1 mmol, 123 mg), phenylacetylene 
(1 mmol, 102 mg), sodium azide (1 mmol, 65 mg), t-BuOH (0,2 cm3, 10% v/v) was stirred for 24 h at room temper-
ature then 24 h at 85 °C and the first work-up protocol was executed. 211 mg (91%) of white crystals was obtained; 
mp: 90.5–93.0 °C (lit.41 94–95 °C); 1H NMR (500 MHz, CDCl3, TMS): δ 7.91 (s, 1H, CH), 7.87–7.83 (m, 2H, Ar) 
7.45–7.41 (m, 2H, Ar), 7.37–7.32 (m, 1H, Ar), 5.21 (s, 2H, NCH2CO), 4.29 (q, J = 7.1 Hz, 2H, OCH2CH3), 1.32 (t, 
J = 7.1 Hz, 3H, OCH2CH3); 13C NMR (126 MHz, CDCl3, TMS): δ 166.4, 148.0, 130.4, 128.8, 128.2, 125.8, 121.4, 
62.4, 50.9, 14.0.
4-(4-phenyl-1H-1,2,3-triazol-1-yl)butyl acetate (9a). 4-Bromobutyl acetate (1 mmol, 195 mg), phenylacetylene 
(1 mmol, 102 mg), sodium azide (1 mmol, 65 mg) was stirred for 24 h at 85 °C and the first work-up protocol was 
executed. 255 mg (98%) of off-white solid was obtained; mp: 57.0–60.0 °C; 1H NMR (500 MHz, CDCl3, TMS): δ 
7.84–7.81 (m, 2H, Ar), 7.76 (s, 1H, CH), 7.44–7.40 (m, 2H, Ar), 7.35–7.31 (m, 1H, Ar), 4.44 (t, J = 7.2 Hz, 2H, 
NCH2CH2CH2CH2), 4.11 (t, J = 6.4 Hz, 2H, CH2CH2CH2CH2O), 2.09–1.98 (m, 2H, CH2CH2CH2CH2O) 2.05 (s, 
3H, OCCH3), 1.74–1.67 (m, 2H, CH2CH2CH2CH2O); 13C-NMR (126 MHz, CDCl3, TMS): δ 170.9, 147.6, 130.6, 
128.8, 128.0, 125.6, 119.9, 63.3, 49.7, 26.9, 25.6, 20.8.
1-(4-methylphenyl)-2-(4-phenyl-1H-1,2,3-triazol-1-yl)propan-1-one (10a). 2-bromo-1-(4-methylphenyl)
propan-1-one (0.50 mmol, 114 mg), phenylacetylene (0.50 mmol, 51 mg), sodium azide (0.50 mmol, 65 mg), 
t-BuOH (0.2 cm3, 10% v/v) was stirred for 48 h at room temperature. Colored resin solidified in a fridge at −15 °C. 
Solids was stirred with 2 cm3 of Et2O. Ether was removed. 135 mg (94%) of white solid mp: 101–101.5 °C, 1H NMR 
(500 MHz; DMSO-d6; TMS): δ 8.79 (s, 1H), 8.01–7.99 (m, 2H), 7.88 (dd, J = 8.3, 1.2, 2H), 7.47–7.44 (m, 2H), 7.38 
(d, J = 7.9, 2H), 7.36–7.32 (m, 1H), 6.73 (q, J = 7.2, 1H), 2.38 (s, 3H), 1.81 (d, J = 7.2, 3H).
13C NMR (126 MHz; DMSO-d6; TMS): δ 194.9, 146.7, 145.3, 131.7, 131.1, 130.1, 129.36, 129.30, 128.3, 125.6, 
121.8, 60.1, 21.7, 18.2.
2-[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]-1-(4-methylphenyl)propan-1-one (10b). 2-bromo-1-
(4-methylphenyl)propan-1-one (0.50 mmol, 114 mg), phenylacetylene (0.50 mmol, 51 mg), sodium azide 
(0.50 mmol, 65 mg), t-BuOH (0.2 cm3, 10% v/v) was stirred for 48 h at room temperature. Colored resin solidified 
in a fridge at −15 °C. Solids was stirred with 2 cm3 of Et2O. Ether was removed. 116 mg (96%) of white solid mp: 
122–123 °C, 1H NMR (500 MHz; DMSO-d6; TMS): δ 8.13 (s, 1H), 7.96–7.94 (m, 2H), 7.38–7.36 (m, 2H), 6.63 (q, 
J = 7.2, 1H), 5.22 (s, 1H), 4.53 (s, 2H), 2.38 (s, 3H), 1.72 (d, J = 7.2, 3H), 13C NMR (126 MHz; DMSO): δ 194.8, 
148.4, 145.2, 131.8, 130.0, 129.2, 123.0, 59.6, 55.5, 21.7, 18.2.
1-(4-nitrophenyl)-4-phenyl-1H-1,2,3-triazole (11a). Synthesized according to conditions A of the general pro-
cedure. 1-fluoro-2-nitrobenzene (1 mmol, 141 mg), phenylacetylene (1 mmol, 102 mg), sodium azide (1 mmol, 
65 mg). After 24 h a NMR sample was prepared. Product was not isolated.
[1-(4-nitrophenyl)-1H-1,2,3-triazol-4-yl]methanol (11b). Synthesized according to conditions A of the gen-
eral procedure. 1-fluoro-2-nitrobenzene (1 mmol, 141 mg), propargyl alcohol (1 mmol, 56 mg), sodium azide 
(1 mmol, 65 mg). After 24 h a NMR sample was prepared. Product was not isolated.
2-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]quinoline (12a). Synthesized according to conditions B of the gen-
eral procedure. 2-(Bromomethyl)-quinoline (0.50 mmol, 111 mg), phenylacetylene (0.55 mmol, 56 mg), sodium 
azide (0.50 mmol, 33 mg). After 30 min the first work-up protocol was executed. 138 mg (99%) of beige solid 
was obtained; mp: 160 °C (lit.23 160–162 °C); 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.74 (s, 1H, Ar), 8.42 (d, 
J = 8.5 Hz, 1H, Ar), 8.00 (dd, J = 8.5 Hz, 4.1 Hz, 2H, Ar), 7.88 (d, J = 7.7 Hz, 2H, Ar), 7.79 (appt, J = 7.8 Hz, 1H, 
Ar), 7.63 (appt, J = 7.5 Hz, 1H, Ar), 7.45 (appt, J = 7.7 Hz, 3H, Ar), 7.34 (appt, J = 7.4 Hz, 1H, Ar), 5.97 (2H, s, 
ArCH2N); 13C NMR (101 MHz; DMSO-d6; TMS): δ 154.7, 148.4, 147.7, 137.8, 130.5, 130.3, 129.2, 128.8, 128.2, 
127.8, 127.6, 127.2, 125.7, 120.2, 119.7, 56.5.
2-[(4-butyl-1H-1,2,3-triazol-1-yl)methyl]quinoline (12b). Synthesized according to conditions B of the gen-
eral procedure. 2-(Bromomethyl)-quinoline (0.50 mmol, 111 mg), 1-hexyne (0.55 mmol, 45 mg), sodium azide 
(0.50 mmol, 33 mg). After 30 min the first work-up protocol was executed. 107 mg (85%) of beige solid was 
obtained; mp: 49–50 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.39 (d, J = 8.6 Hz, 1H, Ar), 8.01–7.95 (m, 3H, 
Ar), 7.82–7.76 (m, 1H, Ar), 7.63 (appt, J = 8.2 Hz, 1H, Ar), 7.32 (d, J = 8.5 Hz, 1H, Ar), 5.86 (s, 2H, ArCH2N), 
2.64 (t, J = 7.6 Hz, 2H, CH2CH2CH2CH3), 1.59 (appquint, J = 7.6 Hz, 2H, CH2CH2CH2CH3), 1.33 (appsextet, 
J = 7.4 Hz, 2H, CH2CH2CH2CH3), 0.89 (t, J = 7.3 Hz, 3H, CH2CH2CH2CH3). 13C NMR (101 MHz; DMSO-d6; 
TMS): δ 156.3, 147.6, 137.8, 130.5, 129.1, 128.4, 127.5, 127.2, 123.2, 120.2, 55.4, 31.6, 25.1, 22.1, 14.1;
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{1-[(quinolin-2-yl)methyl]-1H-1,2,3-triazol-4-yl}methanol (12c). Synthesized according to conditions B of the 
general procedure. 2-(Bromomethyl)-quinoline (0.50 mmol, 111 mg) propargyl alcohol (0.55 mmol, 31 mg), 
sodium azide (0.50 mmol, 33 mg). After 30 min the first work-up protocol was executed. 106 mg (88%) of white 
solid was obtained; mp: 110 °C (lit.23 109–111 °C); 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.41 (d, J = 8.5 Hz, 
1H, Ar), 8.13 (s, 1H), 7.99 (d, J = 8.7 Hz, 2H, Ar), 7.79 (appt, J = 7.8 Hz, 1H, Ar), 7.63 (appt, J = 7.7 Hz, 1H, Ar), 
7.36 (d, J = 8.5 Hz, 1H, Ar), 5.90 (s, 2H, ArCH2N), 5.19 (t, J = 5.7 Hz, 1H, OH), 4.55 (d, J = 5.6 Hz, 2H, CH2OH); 
13C NMR (101 MHz; DMSO-d6; TMS): δ 156.3, 148.8, 147.4, 138.0, 130.6, 129.1, 128.4, 127.5, 127.3, 124.2, 120.3, 
55.5, 55.4.
8-chloro-2-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]quinoline (13a, C18H13ClN4). Synthesized according to con-
ditions B of the general procedure. 2-(Bromomethyl)-8-chloroquinoline (0.50 mmol, 128 mg), phenylacetylene 
(0.50 mmol, 51 mg), sodium azide (0.50 mmol, 33 mg). After 6 min the first work-up protocol was executed and 
the residue was recrystallized from EtOH-MTBE, 80 mg (50%) of a white crystalline solid was obtained; mp: 131–
132 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.78 (s, 1H, CH), 8.51 (d, J = 8.5 Hz, 1H, Ar), 8.00 (d, J = 7.6 Hz, 
1H, Ar), 7.99 (d, J = 7.6 Hz, 1H, Ar) 7.89 (d, J = 7.3 Hz, 1H, Ar), 7.89 (d, J = 7.3 Hz, 1H, Ar) 7.61 (s, 1H, Ar), 7.49 
(d, J = 8.6 Hz, 1H, Ar), 7.46 (appt, J = 7.7 Hz, 2H, Ar), 7.35 (appt, J = 7.4 Hz, 1H, Ar), 6.04 (s, 2H, ArCH2N); 13C 
NMR (101 MHz; DMSO-d6; TMS): δ 156.9, 147.1, 143.3, 138.8, 132.5, 131.2, 130.6, 129.4, 129.1, 128.4, 127.9, 
127.5, 125.7, 123.1, 121.1, 55.7; HRMS (m/z): [M-H]¯ calcd. for C18H1335ClN4, 319.0756; found, 319.0755.
2-[(4-butyl-1H-1,2,3-triazol-1-yl)methyl]-8-chloroquinoline (13b, C16H17ClN4). Synthesized according to 
conditions A of the general procedure. 2-(Bromomethyl)-8-chloroquinoline (0.50 mmol, 128 mg), 1-hexyne 
(0.50 mmol, 41 mg), sodium azide (0.50 mmol, 33 mg), t-BuOH (0.2 cm3, 10% v/v); After 24 h the first work-up 
protocol was executed and after recrystallization from MTBE-EtOH, 101 mg (65%) of a pale yellow solid was 
obtained; mp: 65–67 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.48 (dd, J = 8.5 Hz, 0.8 Hz, 1H, Ar), 8.05 
(d, J = 0.8 Hz, 1H, CH), 8.00–7.96 (m, 2H, Ar), 7.60 (apptd, J = 7.9 Hz, 0.9 Hz, 1H, Ar), 7.38 (dd, J = 8.5 Hz, 
1.0 Hz, 1H, Ar), 5.93 (s, 2H, ArCH2N), 2.65 (t, J = 7.5 Hz, 2H, CH2CH2CH2CH3), 1.6 (appquint, J = 7.5 Hz, 
2H, CH2CH2CH2CH3), 1.32 (appsextet, J = 7.5 Hz, 2H, CH2CH2CH2CH3), 0.88 (apptd, J = 7.4 Hz, 0.8 Hz, 3 H, 
CH2CH2CH2CH3). 13C NMR (101 MHz; DMSO-d6; TMS): δ 157.2, 147.7, 143.2, 138.6, 132.5, 130.6, 129.0, 127.9, 
127.5, 123.5, 121.0, 55.3, 31.6, 25.1, 22.1, 14.1; HRMS (m/z): [M-H]¯ calcd. for C16H1735ClN4, 299.1069; found, 
299.1067.
{1-[(8-chloroquinolin-2-yl)methyl]-1H-1,2,3-triazol-4-yl}methanol (13c, C13H11ClN4). Synthesized according 
to conditions B of the general procedure 2-(Bromomethyl)-8-chloroquinoline (0.50 mmol, 128 mg), propargyl 
alcohol (0.50 mmol, 28 mg), sodium azide (0.50 mmol, 33 mg). Reaction was carried for 15 min. After recrystalli-
zation from EtOH-MTBE 90 mg (65%) of an off-white solid was obtained; mp: 116–119 °C; 1H NMR (400 MHz; 
DMSO-d6; TMS): δ 8.49 (d, J = 8.5 Hz, 1H, Ar), 8.17 (s, 1H, CH), 7.99 (d, J = 8.0 Hz, 1H, Ar), 7.98 (d, J = 7.6 Hz, 
1H, Ar) 7.62 (d, J = 7.8 Hz, 1H, Ar), 7.39 (d, J = 8.5 Hz, 1H, Ar), 5.96 (s, 2H, ArCH2N), 5.21 (t, J = 5.7 Hz, 1H, 
OH), 4.56 (d, J = 5.6 Hz, 2H, CH2OH). 13C NMR (101 MHz; DMSO-d6; TMS): δ 157.2, 148.9, 143.3, 138.7, 132.5, 
130.6, 129.0, 127.9, 127.5, 124.3, 121.1, 55.6, 55.4; HRMS (m/z): [M-H]¯ calcd. for C13H1135ClN4, 273.0549; found, 
273.0547.
1-{1-[(8-chloroquinolin-2-yl)methyl]-1H-1,2,3-triazol-4-yl}ethan-1-ol (13d, C14H13ClN4). Synthesized according 
to conditions B of the general procedure. 2-(Bromomethyl)-8-chloroquinoline (0.50 mmol, 128 mg), but-3-yn-
2-ol (0.50 mmol, 35 mg), sodium azide (0.50 mmol, 33 mg). After 20 min the first work-up protocol was executed 
and after recrystallization from EtOH-MTBE 72 mg (50%) of a beige solid was obtained; mp: 141–142 °C. 1H 
NMR (400 MHz; DMSO-d6; TMS): δ 8.49 (d, J = 8.5 Hz, 1H, Ar), 8.13 (s, 1H, CH), 7.99 (d, J = 8.0 Hz, 1H, Ar), 
7.97 (d, J = 7.6 Hz, 1H, Ar), 7.60 (appt, J = 7.8 Hz, 1H, Ar), 7.40 (d, J = 8.5 Hz, 1H, Ar), 5.95 (s, 2H, ArCH2N), 
5.27 (d, J = 4.9 Hz, 1H, OH), 4.87 (appquint, J = 6.3 Hz, 1H, CHOH), 1.43 (d, J = 6.5 Hz, 3 H, CH3). 13C NMR 
(101 MHz; DMSO-d6; TMS): δ 157.2, 153.5, 143.3, 138.7, 132.5, 130.6, 129.0, 127.9, 127.5, 122.9, 121.1, 62.1, 55.4, 
24.3; HRMS (m/z): [M-H]¯ calcd. for C14H1335ClN4, 287.0705; found 287.0701.
2-({4-[(benzyloxy)methyl]-1H-1,2,3-triazol-1-yl}methyl)-8-chloroquinoline (13e, C20H17ClN4). Synthesized 
according to conditions B of the general procedure. 2-(Bromomethyl)-8-chloroquinoline (0.50 mmol, 128 mg), 
benzyl propargyl ether (0.50 mmol, 73 mg), sodium azide (0.50 mmol, 33 mg). After 30 min the first work-up 
protocol was executed and after recrystallization from EtOH-MTBE 109 mg (60%) of a pale yellow solid was 
obtained; mp: 65–68 °C. 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.49 (d, J = 8.5 Hz, 1H, Ar), 8.36 (s, 1H, CH), 
7.99 (d, J = 7.9 Hz, 1H, Ar), 7.98 (d, J = 7.4 Hz, 1H, Ar), 7.61 (appt, J = 7.8 Hz, 1H, Ar), 7.44 (d, J = 8.5 Hz, 1H, 
Ar), 7.27–7.37 (m, 5 H, Ar), 6.00 (s, 2H, ArCH2N), 4.63 (s, 2H, OCH2Ar), 4.55 (s, 2H, triazole-CH2OCH2Ar). 
13C NMR (101 MHz; DMSO-d6; TMS): δ 144.7, 143.3, 138.7, 138.6, 132.5, 130.6, 129.0, 128.7, 128.1, 127.9, 127.5, 
125.7, 121.1, 71.6, 63.4, 55.4; HRMS (m/z): [M-H]¯ calcd. for C20H1735ClN4, 363.1018; found 363.1021.
4-{1-[(8-chloroquinolin-2-yl)methyl]-1H-1,2,3-triazol-4-yl}-N,N-dimethylaniline (13 f, C20H18ClN5). Synthesized 
according to conditions B of the general procedure. 2-(Bromomethyl)-8-chloroquinoline (0.50 mmol, 128 mg), 
4-ethynyl-N,N-dimethylaniline (0.50 mmol, 73 mg), sodium azide (0.50 mmol, 33 mg). After 40 min the first 
work-up protocol was executed and after recrystallization from EtOH-MTBE 95 mg (52%) of a beige solid was 
obtained; mp: 127–128 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.55 (s, 1H, CH), 8.50 (d, J = 8.5 Hz, 1H, Ar), 
8.00 (d, J = 8.0, 1H, Ar), 7.99 (d, J = 7.2 Hz, 1H, Ar), 7.68 (d, J = 8.6 Hz, 2H, Ar), 7.61 (appt, J = 7.8 Hz, 1H, Ar), 
7.46 (d, J = 8.5 Hz, 1H, Ar), 6.79 (d, J = 8.7 Hz, 2H, Ar), 5.99 (s, 2H, ArCH2N), 2.93 (s, 6 H, N(CH3)2). 13C NMR 
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(101 MHz; DMSO-d6; TMS): δ 157.1, 150.5, 147.8, 143.3, 138.8, 132.5, 130.6, 129.0, 127.9, 127.6, 126.6, 121.1, 
119.1, 112.8, 55.6; HRMS (m/z): [M-H]¯ calcd. for C20H1835ClN5, 362.1178; found, 362.1174.
2-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]quinazolin-4(3 H)-one (14a, C17H13N5O). Synthesized according to 
conditions B of the general procedure. 2-Bromomethyl-4-quinazolone (0.50 mmol, 119 mg), phenylacetylene 
(0.55 mol. 65 mg), sodium azide (0.50 mmol, 33 mg), t-BuOH (0.2 cm3, 10% v/v). After 5 h the second work-up 
protocol was executed. 108 mg (73%) of a white solid was obtained; mp: 283 °C; 1H NMR (400 MHz; DMSO-d6; 
TMS): δ 12.67 (s, 1H, OCNH), 8.70 (s, 1H, CH), 8.17–8.09 (dd, J = 7.9 Hz, 1.0 Hz, 1H, Ar), 7.89 (appd, J = 7.3 Hz, 
2H, Ar), 7.82–7.74 (appt, 1H, Ar), 7.55 (m, 2H, Ar), 7.47 (t, J = 7.6 Hz, 2H, Ar), 7.35 (appt, J = 7.4 Hz, 1H, Ar), 
5.67 (s, 2H, ArCH2N); 13C NMR (101 MHz; DMSO-d6; TMS): δ 161.9, 151.5, 148.6, 146.8, 135.0, 131.1, 129.4, 
128.4, 127.7, 127.4, 126.3, 125.7, 123.4, 121.8, 51.9; HRMS (m/z): [M-H]¯ calcd. for C17H13N5O, 302.1047; found, 
302.1042.
2-[(4-butyl-1H-1,2,3-triazol-1-yl)methyl]quinazolin-4(3H)-one (14b, C15H17N5O). Synthesized according to con-
ditions B of the general procedure. 2-Bromomethyl-4-quinazolone (0.50 mmol, 119 mg), 1-hexyne (0.55 mmol, 
45 mg), sodium azide (0.50 mmol, 33 mg), t-BuOH (0.2 cm3, 10% v/v); After 1.5 h the second work-up pro-
tocol was executed. 103 mg (73%) of a beige solid was obtained; mp: 262 °C; 1H NMR (400 MHz; DMSO-d6; 
TMS): δ 12.58 (s, 1H, OCNH), 8.12 (dd, J = 8.3 Hz, 1.5 Hz, 1H, Ar), 7.97 (s, 1H, CH), 7.82–7.76 (m, 1H, Ar), 
7.55–7.50 (m, 2H, Ar), 5.53 (s, 2H, ArCH2N), 2.65 (t, J = 7.5 Hz, 2H, CH2CH2CH2CH3), 1.60 (tt, J = 7.5 Hz, 2H, 
CH2CH2CH2CH3), 1.35 (tq, J = 7.3 Hz, 2H, CH2CH2CH2CH3), 0.91 (t, J = 7.4 Hz, 3 H, CH2CH2CH2CH3); 13C 
NMR (101 MHz; DMSO-d6; TMS): δ 161.8, 151.7, 148.6, 147.3, 135.0, 127.6, 127.4, 126.3, 123.8, 121.7, 51.6, 31.5, 
25.1, 22.1, 14.1; HRMS (m/z): [M-H]¯ calcd. for C15H17N5O, 282.1360; found, 282.1355.
2-{[4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl]methyl}quinazolin-4(3H)-one (14c, C12H11N5O2). Synthesized 
according to conditions B of the general procedure. 2-Bromomethyl-4-quinazolone (0.50 mmol, 119 mg), prop-
argyl alcohol (0.55 mmol, 31 mg), sodium azide (0.50 mmol, 33 mg), t-BuOH (0.2 cm3, 10% v/v); After 1 h the 
second work-up protocol was executed. 85 mg (70%) of an off-white solid was obtained; mp: 235 °C; 1H NMR 
(400 MHz; DMSO-d6; TMS): δ 12.57 (s, 1H, OCNH), 8.13 (d, J = 1.2 Hz, 1H, Ar), 8.10 (s, 1H, CH), 7.83–7.75 (m, 
1H, Ar), 7.53 (dd, J = 13.8 Hz, 7.3 Hz, 2H, Ar), 5.58 (s, 2H, ArCH2N), 5.22 (s, 1H, OH), 4.56 (s, 2H, CH2OH); 13C 
NMR (101 MHz; DMSO-d6; TMS): δ 161.9, 151.7, 148.5, 148.5, 135.0, 127.6, 127.4, 126.3, 124.6, 121.7, 55.5, 51.7; 
HRMS (m/z): [M-H]¯ calcd. for C12H11N5O2, 256.0840; found, 256.0835.
2-{[4-(1-hydroxyethyl)-1H-1,2,3-triazol-1-yl]methyl}quinazolin-4(3H)-one (14d, C13H13N5O2). Synthesized 
according to conditions B of the general procedure. 2-Bromomethyl-4-quinazolone (0.50 mmol, 119 mg), but-
3-yn-2-ol (0.55 mmol, 39 mg), sodium azide (0.50 mmol, 33 mg), t-BuOH (0.2 cm3, 10% v/v). After 30 min the sec-
ond work-up protocol was executed. 97 mg (72%) of a beige solid was obtained; mp: 244 °C; 1H NMR (400 MHz; 
DMSO-d6; TMS): δ 12.63 (s, 1H, OCNH), 8.12 (d, J = 7.7 Hz, 1H, Ar), 8.05 (s, 1H, CH), 7.80 (t, J = 7.4 Hz, 1H, 
Ar), 7.54 (dd, J = 15.8 Hz, 7.9 Hz, 2H, Ar), 5.55 s, (2H, ArCH2N), 5.29 (d, J = 4.8 Hz, 1H, OH), 4.94–4.78 (m, 1H, 
CHOH), 1.43 (d, J = 6.5 Hz, 3 H, CH3). 13C NMR (101 MHz; DMSO-d6; TMS): δ 161.9, 153.1, 151.7, 148.6, 135.0, 
127.6, 127.4, 126.3, 123.2, 121.7, 62.1, 51.8, 24.2; HRMS (m/z): [M-H]¯ calcd. for C13H13N5O2, 270.0996; found, 
270.0992.
2-({4-[(benzyloxy)methyl]-1H-1,2,3-triazol-1-yl}methyl)quinazolin-4(3H)-one (14e, C19H17N5O2). Synthesized 
according to conditions B of the general procedure. 2-Bromomethyl-4-quinazolone (0.50 mmol, 119 mg), benzyl 
propargyl ether (0.55 mmol, 80 mg), sodium azide (0.50 mmol, 33 mg), t-BuOH (0.2 cm3, 10% v/v). After 15 min, 
the second work-up protocol was executed. 164 mg (95%) of a white solid was obtained; mp: 226 °C; 1H NMR 
(400 MHz; DMSO-d6; TMS): δ 12.64 (s, 1H, OCNH), 8.27 (s, 1H, CH), 8.12 (dd, J = 8.2 Hz, 1.3 Hz, 1H, Ar), 
7.81–7.74 (m, 1H, Ar), 7.52 (appt, J = 7.1 Hz, 2H, Ar), 7.38–7.33 (m, 4 H, Ar), 7.30 (td, J = 8.7 Hz, 4.1 Hz, 1H, 
Ar), 5.61 (s, 2H, ArCH2N), 4.63 (s, 2H, ArCH2O), 4.56 (s, 2H, OCH2Ar); 13C NMR (101 MHz; DMSO-d6; TMS): 
δ 161.9, 151.7, 148.5, 144.4, 138.6, 135.0, 128.7, 128.1, 128.0, 127.5, 127.4, 126.3, 126.0, 121.8, 71.7, 63.3, 51.7; 
HRMS (m/z): [M-H]− calcd. for C19H17N5O2, 346.1309; found, 346.1303.
2-({4-[4-(dimethylamino)phenyl]-1H-1,2,3-tr iazol-1-yl}methyl)quinazolin-4(3H)-one (14 f, 
C19H18N6O). Synthesized according to conditions B of the general procedure. 2-Bromomethyl-4-quinazolone 
(0.50 mmol, 119 mg), 4-ethynyl-N,N-dimethylaniline (0.55 mmol, 79 mg), sodium azide (0.50 mmol, 33 mg), 
t-BuOH (0.2 cm3, 10% v/v). After 30 min the second work-up protocol was executed. 152 mg (88%) of a light 
brown solid was obtained; mp: 276 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 12.65 (s, 1H, OCNH), 8.47 (s, 1H, 
CH), 8.13 (d, J = 7.8 Hz, 1H, Ar), 7.78 (t, J = 7 .6 Hz, 1H, Ar), 7.69 (d, J = 8.7 Hz, 2H, Ar), 7.54 (dd, J = 17.8 Hz, 
7.9 Hz, 2H, Ar), 6.79 (d, J = 8.7 Hz, 2H, Ar), 5.61 (s, 2H, ArCH2N), 2.94 (s, 6 H, N(CH3)2). 13C NMR (101 MHz; 
DMSO-d6; TMS): δ 161.9, 151.6, 150.5, 148.6, 147.4, 135.0, 127.6, 127.4, 126.6, 126.3, 121.8, 121.4, 119.0, 112.8, 
51.8; HRMS (m/z): [M-H]¯ calcd. for C19H18N6O, 345.1469; found, 345.1463.
Organic azides precursors. 2-(bromomethyl)-quinoline (12). The compound was synthesized following 
the reported protocol42. A white solid yield: 42%; 1H NMR (400 MHz; DMSO-d6; TMS): δ 8.16 (d, J = 8.4 Hz, 1H, 
ArH), 8.07 (d, J = 8.4 Hz, 1H, ArH), 7.80 (dd, J = 8.0 Hz, 1.2Hz, 1H, ArH), 7.74–7.70 (m, 1H, ArH), 7.57–7.52 (m, 
2H, ArH), 4.71 (s, 2H, BrCH2);
2-(bromomethyl)-8-chloroquinoline (13). 8-Chloro-2-methylquinoline (1.78 g, 10 mmol) and NBS (1.78 g, 
10 mmol) was loaded into a three-neck 250 cm3 flask. The neck was equipped with a reflux condenser, a 
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thermometer and a septum stopper. Ethyl acetate (100 cm3) and water (50 cm3) were introduced and the reaction 
vessel was flushed with nitrogen and finally the condenser was attached to a nitrogen-filled balloon. A mag-
netic stirrer was engaged and the flask was immersed into an oil bath. At the point at which the temperature of 
the reaction mixture exceeded 70 °C, 1 cm3 of an AIBN hydrochloride (20 mg, 0.12 mmol) aqueous solution was 
introduced dropwise over two-hour period through the septum. After 4 h, the organic phase was separated and 
washed with water (2 × 100 cm3). Silica-gel (40 g) was loaded into the solution and the solvent was removed under 
reduced pressure. The material was packed into a chromatographic column and eluted with hexanes-CH2Cl2 
(3:1 v/v). The product was collected as a solution in a second fraction. Ethyl acetate was removed under reduced 
pressure to yield 768 mg (30%) as white crystals, mp: 129 °C (lit.43 127 °C); 1H NMR (400 MHz; DMSO-d6; TMS): 
δ 8.51 (d, J = 8.5 Hz, 1H, ArH-3), 8.00 (dd, J = 7.7 Hz, 1.4 Hz, 1H, ArH-7), 7.98 (dd, J = 6.9 Hz, 1.3 Hz, 1H, ArH-5), 
7.80 (d, J = 8.5 Hz, 1H, ArH-4), 7.62 (dd, J = 8.1 Hz, 7.6 Hz, 1H, ArH-6), 4.91 (s, 2H, ArCH2Br).
2-(bromomethyl)-3H-quinazolin-4-one (14). The compound was prepared following the reported proto-
col44. M.p.: 229–231 °C; 1H NMR (400 MHz; DMSO-d6; TMS): δ 12.57 (s, 1H), 8.13 (d, J = 7.9 Hz, 1H), 7.84 (t, 
J = 7.6 Hz, 1H), 7.68 (d, J = 8.1 Hz, 1H), 7.55 (t, J = 7.5 Hz, 1H), 4.41 (s, 2H).
2-(iodomethyl)-3H-quinazolin-4-one (15, C9H7IN2O). A suspension of 2-methyl-4(3H)-quinazolinone (1.6 g, 
10 mmol) and iodine (2.54 g, 10 mmol) in 50 cm3 of MeOH was refluxed in a balloon assembly for 16 h). The pre-
cipitate was filtered and rinsed on a funnel with a portion of MeOH in order to obtain the product – 1.74 g (61%) 
as a white fluffy solid that was used without further purification, mp: 219–221 °C (decomp.);1H NMR (500 MHz; 
DMSO-d6; TMS): δ 12.44 (s, 1H, NH), 8.10 (ddd, J = 7.9 Hz, 1.6 Hz, 0.5 Hz, 1H, ArH-5), 7.81 (ddd, J = 8.2 Hz, 
7.1 Hz, 1.6 Hz, 1H, ArH-7), 7.63 (ddd, J = 8.2 Hz, 1.1 Hz, 0.6 Hz, 1H, ArH-8), 7.52 (ddd, J = 8.0 Hz, 7.1 Hz, 1.1 Hz, 
1H, ArH-6), 4.25 (s, 2H, ArCH2I); 13C NMR (101 MHz; DMSO-d6; TMS): δ 162.0, 155.3, 149.0, 135.1, 127.43, 
127.36, 126.3, 121.3, 55.4; HRMS (m/z): [M + H]+ calcd. for C9H7IN2O, 286.9676; found, 286.9676.
Data availability. The data generated or analysed during this study are included in this published article or 
in its Supplementary Information files.
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